Arabic Arabic English English French French German German
dark

vTv Therapeutics Shares Updated Corporate Presentation

vTv Therapeutics Inc. is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Yorkshire and Humber AHSN showcase innovations to senior NHS figures

Next Post

Evasc Neurovascular Announces Enrollment of First Patient in the French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR)

Related Posts
Total
0
Share